Iovance Biotherapeutics, Inc. IOVA
We take great care to ensure that the data presented and summarized in this overview for IOVANCE BIOTHERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IOVA
View all-
Vanguard Group Inc Valley Forge, PA27.5MShares$98.8 Million0.0% of portfolio
-
Mhr Fund Management LLC New York, NY24.4MShares$87.7 Million24.02% of portfolio
-
Perceptive Advisors LLC New York, NY22.1MShares$79.4 Million5.46% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$76.2 Million0.0% of portfolio
-
State Street Corp Boston, MA12.2MShares$44 Million0.0% of portfolio
-
Hood River Capital Management LLC Palm Beach Gardens, FL8.99MShares$32.3 Million1.15% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.56MShares$23.6 Million3.38% of portfolio
-
Geode Capital Management, LLC Boston, MA5.87MShares$21.1 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.83MShares$20.9 Million0.03% of portfolio
-
Pictet Asset Management Sa Geneva 73, V85.18MShares$18.6 Million0.04% of portfolio
Latest Institutional Activity in IOVA
Top Purchases
Top Sells
About IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Insider Transactions at IOVA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 14
2025
|
Raj K. Puri Chief Regulatory Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,509
-1.23%
|
$7,527
$3.59 P/Share
|
|
Mar 14
2025
|
Raj K. Puri Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,334
+3.93%
|
-
|
|
Mar 03
2025
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
33,470
-26.48%
|
$133,880
$4.04 P/Share
|
|
Mar 03
2025
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
62,497
+33.09%
|
-
|
|
Mar 03
2025
|
Raj K. Puri Chief Regulatory Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
19,984
-9.28%
|
$79,936
$4.04 P/Share
|
|
Mar 03
2025
|
Raj K. Puri Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
59,999
+21.79%
|
-
|
|
Mar 03
2025
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
95,413
-21.44%
|
$381,652
$4.04 P/Share
|
|
Mar 03
2025
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
223,943
+33.47%
|
-
|
|
Mar 03
2025
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
33,302
-27.55%
|
$133,208
$4.04 P/Share
|
|
Mar 03
2025
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
62,106
+33.94%
|
-
|
|
Mar 03
2025
|
Jean Marc Bellemin Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
31,734
-36.09%
|
$126,936
$4.04 P/Share
|
|
Mar 03
2025
|
Jean Marc Bellemin Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
58,590
+39.99%
|
-
|
|
Jan 14
2025
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,578
-2.61%
|
$7,890
$5.89 P/Share
|
|
Jan 14
2025
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,813
+4.45%
|
-
|
|
Jan 14
2025
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,578
-2.41%
|
$7,890
$5.89 P/Share
|
|
Jan 14
2025
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,813
+4.12%
|
-
|
|
Jan 14
2025
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
9,955
-4.31%
|
$49,775
$5.89 P/Share
|
|
Jan 14
2025
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,835
+8.27%
|
-
|
|
Dec 16
2024
|
Raj K. Puri Chief Regulatory Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,759
-2.36%
|
$26,313
$7.84 P/Share
|
|
Dec 16
2024
|
Raj K. Puri Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,334
+4.98%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 784K shares |
|---|
| Open market or private sale | 50K shares |
|---|---|
| Payment of exercise price or tax liability | 337K shares |